Rapid Genetic Test Developed for an Often Fatal Mitochondrial Disease
By LabMedica International staff writers Posted on 19 Jul 2016 |

Image: Mitochondria. Researchers have inherited mutations in the TMEM126B gene that cause debilitating and often fatal disease from infancy, and have developed a rapid diagnostic test that has already identified 6 patients from 4 families (Image courtesy of Newcastle University).
Researchers have discovered disease-causing inherited mutations in the TMEM126B gene and developed a test providing rapid diagnosis of related mitochondrial disorders. Defects in TMEM126B cause problems with energy generation in muscles, and can lead to muscular weakness, blindness, fatal heart failure, liver failure, learning disability, diabetes, and seizures. There is currently no cure and affected children often die in early infancy.
A team of medics and scientists at Wellcome Trust Centre for Mitochondrial Research, Newcastle University (Newcastle, Tyne & Wear, UK), together with international collaborators identified the mutations and used next generation sequencing (NGS) to develop the test, which provides a result within 2-3 days. Their research confirmed the identity of a mutation in TMEM126B that causes mitochondrial disease affecting Complex I, one of five complexes involved in energy production. TMEM126B normally makes a protein necessary for complex I assembly.
First author Charlotte Alston, PhD student, described the technique, which has already identified 6 patients from 4 families affected by this form of mitochondrial disease: “Identifying a fault in Complex I [...] combined with our custom gene capture and the latest sequencing technology means we can screen many more genes to diagnose this debilitating disease. It means families can get a rapid diagnosis within days rather than the weeks and months that testing can currently take. For families who are waiting on a genetic diagnosis before trying for another baby, or they may already be expecting their next child, time really is of the essence.”
Senior author Professor Rob Taylor said: “The diagnosis of mitochondrial disease is often a complicated and time consuming process. There are over 1,300 potential genes that can lead to disease and, as such, finding the genetic cause is sometimes like looking for a needle in a haystack.”
For a family with one child affected with this type of mitochondrial disease, there is a 25% chance of each further child being affected. Professor Taylor added: “There is sadly no cure for mitochondrial disease so rapid diagnosis means parents who are wanting to have further children can opt for prenatal testing to ensure future children are healthy and without risk of developing severe disease. It provides options for families at risk of an otherwise incurable disease.”
The study, by Alston CL et al, was published July 7, 2016, in the American Journal of Human Genetics.
Related Links:
Newcastle University
Wellcome Trust Centre for Mitochondrial Research
A team of medics and scientists at Wellcome Trust Centre for Mitochondrial Research, Newcastle University (Newcastle, Tyne & Wear, UK), together with international collaborators identified the mutations and used next generation sequencing (NGS) to develop the test, which provides a result within 2-3 days. Their research confirmed the identity of a mutation in TMEM126B that causes mitochondrial disease affecting Complex I, one of five complexes involved in energy production. TMEM126B normally makes a protein necessary for complex I assembly.
First author Charlotte Alston, PhD student, described the technique, which has already identified 6 patients from 4 families affected by this form of mitochondrial disease: “Identifying a fault in Complex I [...] combined with our custom gene capture and the latest sequencing technology means we can screen many more genes to diagnose this debilitating disease. It means families can get a rapid diagnosis within days rather than the weeks and months that testing can currently take. For families who are waiting on a genetic diagnosis before trying for another baby, or they may already be expecting their next child, time really is of the essence.”
Senior author Professor Rob Taylor said: “The diagnosis of mitochondrial disease is often a complicated and time consuming process. There are over 1,300 potential genes that can lead to disease and, as such, finding the genetic cause is sometimes like looking for a needle in a haystack.”
For a family with one child affected with this type of mitochondrial disease, there is a 25% chance of each further child being affected. Professor Taylor added: “There is sadly no cure for mitochondrial disease so rapid diagnosis means parents who are wanting to have further children can opt for prenatal testing to ensure future children are healthy and without risk of developing severe disease. It provides options for families at risk of an otherwise incurable disease.”
The study, by Alston CL et al, was published July 7, 2016, in the American Journal of Human Genetics.
Related Links:
Newcastle University
Wellcome Trust Centre for Mitochondrial Research
Latest Molecular Diagnostics News
- Highly Accurate Biomarkers Could Detect Ovarian Cancer Before Clinical Diagnosis
- New Gene Tool to Enable Earlier Detection and Treatment of Cardiometabolic Diseases
- Genetic Tool Predicts Lithium Responsiveness in Bipolar Disorder Patients
- Genetic Testing Benefits Critically Ill Adults
- Testing Blood Samples for Proteins Can Reveal Malaria Severity
- Blood Test Detects Multiple Sclerosis Risk Years Before Onset of Symptoms
- Blood-Based Biomarkers Could Detect Alzheimer's as Early as Middle Age
- RNA Screening Test Could Detect Colon Polyps Before They Become Cancerous
- New RT-LAMP Assay Offers Affordable and Reliable Pathogen Detection for Resource-Limited Settings
- New Biomarker Panel to Enable Early Detection of Pancreatic Cancer
- Ultrarapid Whole Genome Sequencing for Neonatal and Pediatric Patients Delivers Results In 48 Hours
- AI-Enabled Blood Test Demonstrates Diagnostic, Prognostic and Predictive Utility Across Cancer Continuum
- DNA Methylation Signatures of Aging Could Help Assess Mortality Risk
- Molecular Diagnostics System Provides Lab-Quality Results at POC
- Cellular Signature Identifies Patients with Treatment Resistant Prostate Tumors
- MCED Could Be Valuable Supplement to Traditional Cancer Screening Approaches
Channels
Clinical Chemistry
view channel
Skin Swabs Could Detect Parkinson’s Years Before Symptoms Appear
Parkinson’s disease is notoriously difficult to diagnose in its early stages, as motor symptoms do not appear until later in the progression of the disease. The ability to detect the disease up to seven... Read more
New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs
A new clinical chemistry analyzer is designed to provide outstanding performance and maximum efficiency, without compromising affordability, to meet the growing demands of modern laboratories.... Read more
New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
Nucleic acid amplification tests (NAATs) play a key role in diagnosing a wide range of infectious diseases. These tests are generally known for their high sensitivity and specificity, and they can be developed... Read moreHematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read moreImmunology
view channel
New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy
To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more
Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer
Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more
Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes
Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read moreMicrobiology
view channel
Early Detection of Gut Microbiota Metabolite Linked to Atherosclerosis Could Revolutionize Diagnosis
Cardiovascular disease is the leading cause of death worldwide, and atherosclerosis plays a critical role in its development. This chronic condition, characterized by the hardening and narrowing of arteries... Read more
Viral Load Tests Can Help Predict Mpox Severity
Mpox is a viral infection that causes flu-like symptoms and a characteristic rash, which evolves significantly over time and varies between patients. The disease spreads mainly through direct contact with... Read more
Gut Microbiota Analysis Enables Early and Non-Invasive Detection of Gestational Diabetes
Gestational diabetes mellitus is a common metabolic disorder marked by abnormal glucose metabolism during pregnancy, typically emerging in the mid to late stages. It significantly heightens the risk of... Read morePathology
view channel
AI Tool Accurately Determines Breast Cancer Prognosis
A new study has found that cells and tissues surrounding a breast cancer tumor may hold critical information about how patients will respond to treatment. The research, published in the journal Patterns,... Read more
Powerful New Tool Improves Tissue Cancer Analysis
Studying the mix of cell types in human tissue is crucial for understanding diseases like cancer, but it presents significant challenges in both accuracy and scalability. The tumor microenvironment, composed... Read moreTechnology
view channel
Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells
A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Safer, Portable and Low-Cost Imaging Solution to Revolutionize Biomedical Diagnostics
In diagnosing diseases and monitoring treatment, accurate and quick detection of temperature within biological tissues can be crucial, especially in early disease detection. Conventional methods such as... Read more
Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation
Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read moreIndustry
view channel
QuidelOrtho and BÜHLMANN Collaborate on Gastrointestinal Biomarker Tests
QuidelOrtho Corporation (San Diego, CA, USA) and BÜHLMANN Laboratories AG (Schönenbuch, Switzerland) have announced the availability of the BÜHLMANN fCAL turbo and fPELA turbo assays on QuidelOrtho's... Read more